What are the biggest names in biotechnology? We count down the five top biotech stocks based on market cap.
What are the top biotech companies? The following five stocks have market capitalizations worth billions of dollars and operate in countries all around the globe.
Plus, these big-name biotech players have pipelines stuffed with potentially disruptive products — and enough revenue to recover should some of those products fail.
This means that investors can experience the excitement of biotech investing while minimizing risk. Although returns are never guaranteed, company size can insulate investors from volatility.
Top biotech companies to consider
If you’re cautiously interested in biotech stocks, starting with the top companies by market cap could be a good strategy. This list of the largest NASDAQ biotech stocks and NYSE biotech stocks was compiled using Investing.com’s stock screener, and all numbers were current as of June 21, 2022.
Market capitalization: US$271.25 billion
This biopharmaceutical company is one of the most well-known organizations in the industry. AbbVie’s operations are spread throughout 75 countries and its products are sold in over 170 nations.
The Chicago-based company aims to treat a range of diseases in five key areas. Its treatment areas include: virology, whixch includes hepatitis C and HIV; neurodegenerative diseases, such as schizophrenia, Alzheimer’s disease, Parkinson’s disease and multiple sclerosis; immunology, including spondyloarthropathies, hidradenitis suppurativa and uveitis; oncology, which is the treatment of cancer; and general medicine, including women’s health.
In mid-2021, AbbVie announced the submission of a supplemental new drug application to the US Food and Drug Administration (FDA) for atogepant. The company recently completed a successful Phase 3 progress study on the use of atogepant in the treatment of chronic migraines. It is already approved by the FDA to treat adults with episodic migraines and is marketed as QULIPTAin the US.
Market capitalization: US$130.02 billion
Amgen has heavily invested in gene-based research. The biotech company is firmly established as a leader in using advanced human genetics to develop and manufacture therapeutics targeting diseases with unmet medical needs.
Amgen’s Q1 2022 revenue increased by 6 percent over Q1 2021 to reach US$6.2 billion, and it's on track to reach its 2022 total revenue guidance of US$25.4 billion to US$26.5 billion. "We achieved strong, volume-driven growth in the quarter, while launching two very promising first-in-class medicines," CEO Robert A. Bradway said. "We are also advancing a robust pipeline with data for several mid-to-late stage candidates expected during the year."
Market capitalization: US$78.23 billion
For three decades, global biopharmaceutical company Gilead Sciences has developed breakthrough medicines to prevent and treat serious diseases such as HIV, viral hepatitis and cancer. One of its recent successes is Yescarta, a CAR-T cell therapy for blood cancer and the first such therapy for certain types of non-Hodgkin's lymphoma.
Gilead’s Q1 2022 product sales increased 3 percent over Q1 2021 to total US$6.5 billion, primarily driven by higher demand for its HIV therapy Biktarvy, cell therapy products and second-line cancer treatment Trodelvy. The company’s 2022 total product sales guidance stands at US$23.8 billion to US$24.3 billion.
Market capitalization: US$69.55 billion
Biotech leader Regeneron Pharmaceuticals develops and commercializes medicines targeting cancer, pain and a wide variety of diseases, including inflammatory, cardiovascular, metabolic, hematologic and rare diseases.
The FDA has approved nine of the treatments in the company’s portfolio, which also includes a number of product candidates in development. The company’s Regeneron Genetics Center is investigating approaches to speeding up the discovery and development of medicines for serious illnesses. In late May 2022, Regeneron acquired immune-oncology company Checkmate Pharmaceuticals, whose lead investigational candidate, vidutolimod, has demonstrated clinical responses as a monotherapy in patients with PD-1 refractory melanoma.
Market capitalization: US$63.1 billion
Vertex Pharmaceuticals is a global biotech firm focused on developing and commercializing therapies for treating cystic fibrosis. It has a number of approved treatments for cystic fibrosis, and a pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes.
Vertex and its partner CRISPR Therapeutics (NASDAQ:CRSP) are in Phase 3 clinical studies for drug candidate CTX001 as a one-time treatment for severe sickle cell disease and transfusion-dependent beta thalassemia.
This is an updated version of an article originally published by the Investing News Network in 2016.
Don’t forget to follow us @INN_LifeScience for real-time news updates!
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
- Biotech Outlook 2022: When Will the Bear Market End? ›
- How to Invest in Biotechnology | INN ›
- Top 3 Canadian Biotech Stocks of 2022 ›
- 5 Top Biotech ETFs ›
- 7 NASDAQ Oncology Companies (Updated 2022) ›